QCG
ATXS

Quadrant Capital Group’s Astria Therapeutics ATXS Stock Holding History

Quadrant Capital Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$1K – 2404
2021
Q1 		$1K Hold
33
– – ﹤0.01% 2166
2020
Q4 		$0 Buy
+33
New +$588 ﹤0.01% 2291

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Quadrant Capital Group's ATXS Position: Q2 2021 in Review

Quadrant Capital Group sold out of Astria Therapeutics (ATXS) in Q2 2021, closing a stake of 33 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in ATXS in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2021. 58 funds tracked by Wall St. Rank hold ATXS as of Q2 2021.

  • Quadrant Capital Group reported no remaining Astria Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 33 Astria Therapeutics shares in Q2 2021, an estimated $1K.
  • Quadrant Capital Group first reported a position in Astria Therapeutics in Q4 2020 and held it in 2 quarters.
  • Quadrant Capital Group's Astria Therapeutics position peaked at $1K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2021.

Based on Quadrant Capital Group's 13F filing for Q2 2021, filed 9 Aug 2021.